Revenue
2021
2022
2023
2024
2025
InMed Pharmaceuticals Inc. (INM)
Price$1.38Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $4.9M | $4.6M | $1.4M | $1.4M | $1.9M | — |
| Gross profit | $1.7M | $1.1M | $1.4M | $543,546 | — | — |
| Gross margin | 34.53% | 23.94% | 102.73% | 39.80% | — | — |
| Research & development | $2.9M | $3.2M | $3.7M | $0.2 | $5.3M | $5.8M |
| Operating expenses | $9.7M | $9.3M | $9.8M | $17.8M | $9.9M | $9.2M |
| Operating income | −$7.9M | −$8.1M | −$7.9M | −$18.6M | −$10.2M | — |
| Operating margin | −160.20% | −176.92% | −581.92% | −1,361.89% | −535.87% | — |
| EBITDA | −$7.3M | −$7.1M | −$7.7M | −$18.4M | −$10.1M | — |
| EBITDA margin | −146.80% | −153.64% | −567.11% | −1,348.30% | −529.52% | — |
| Net income | −$8.2M | −$7.7M | −$7.9M | −$18.6M | −$10.2M | −$8.9M |
| Net profit margin | −165.14% | −166.94% | −581.92% | −1,361.89% | −535.87% | — |
| Basic EPSper basic share | -$8.36 | -$20.14 | -$65.00 | -$663.40 | -$759.20 | -$855.00 |
| Diluted EPSper diluted share | -$8.36 | -$20.14 | -$65.00 | -$663.40 | -$759.20 | -$855.00 |
Owners
Reported shareholders
14.98%of listed shares
ADAR1 Capital Management, LLC800K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
ADAR1 Capital Management, LLC | 14.98%800K shares |
Vivo Capital, LLC | 14.95%798.38K shares |
Vivo Opportunity, LLC / Vivo Opportunity Cayman, LLC / Vivo Opportunity Fund Holdings, L.P. / Vivo Opportunity Cayman Fund, L.P. | ≈14.81%790.98K shares |
Squadron Capital Management LLC | 6.09%325K shares |
Ikarian Capital, LLC | 4.59%245.03K shares |
Ursa Fund Management, LLC | 2.36%125.8K shares |
MONTANOVA CAPITAL, LLC | 1.87%100K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 1.39%74.24K shares |
SABBY MANAGEMENT, LLC | 0.84%44.97K shares |
JANE STREET GROUP, LLC | 0.81%43.08K shares |
Venrock Adviser, LLC | 0.61%32.69K shares |
CITADEL ADVISORS LLC | 0.49%26.08K shares |
SEVEN GRAND MANAGERS, LLC | 0.47%25K shares |
Scientech Research LLC | 0.29%15.46K shares |
Crestwood Advisors Group, LLC | 0.28%14.9K shares |
TWO SIGMA SECURITIES, LLC | 0.20%10.95K shares |
Stratos Wealth Partners, LTD. | 0.20%10.76K shares |
Private Wealth Management Group, LLC | 0.09%5K shares |
SBI Securities Co., Ltd. | <0.01%300 shares |
Banque Cantonale Vaudoise | <0.01%6 shares |
Percentages use 5.34M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 8, 2026Form 4 | Vivo Opportunity, LLC +3TenPercentOwner | BuyCommon Shares · indirect | 3.0K | $1.52 | $4.5K | 72.5K |
| Jun 8, 2026Form 4 | Vivo Opportunity, LLC +3TenPercentOwner | BuyCommon Shares · indirect | 29.5K | $1.52 | $44.9K | 718.4K |
| Jun 5, 2026Form 4 | Vivo Opportunity, LLC +3TenPercentOwner | BuyCommon Shares · indirect | 5.0K | $1.57 | $7.9K | 69.6K |
| Jun 5, 2026Form 4 | Vivo Opportunity, LLC +3TenPercentOwner | BuyCommon Shares · indirect | 50.0K | $1.57 | $78.4K | 688.9K |
| Jun 4, 2026Form 4 | Vivo Opportunity, LLC +3TenPercentOwner | BuyCommon Shares · indirect | 618 | $1.57 | $970.26 | 64.5K |